keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant breast

keyword
https://www.readbyqxmd.com/read/29452344/overexpression-of-blm-promotes-dna-damage-and-increased-sensitivity-to-platinum-salts-in-triple-negative-breast-and-serous-ovarian-cancers
#1
N J Birkbak, Y Li, S Pathania, A Greene-Colozzi, M Dreze, C Bowman-Colin, Z Sztupinszki, M Krzystanek, M Diossy, N Tung, P D Ryan, J E Garber, D P Silver, J D Iglehart, Z C Wang, D Szuts, Z Szallasi, A L Richardson
Background: Platinum based therapy is an effective treatment for a subset of triple negative breast cancer and ovarian cancer patients. In order to increase response rate and decrease unnecessary use, robust biomarkers that predict response to therapy are needed. Patients and methods: We performed an integrated genomic approach combining differential analysis of gene expression and DNA copy number in sensitive compared to resistant triple negative breast cancers in two independent neoadjuvant cisplatin treated cohorts...
February 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29449773/potential-breast-anticancer-drug-targets-revealed-by-differential-gene-regulatory-network-analysis-and-molecular-docking-neoadjuvant-docetaxel-drug-as-a-case-study
#2
Adel Aloraini, Karim M ElSawy
Understanding gene-gene interaction and its causal relationship to protein-protein interaction is a viable route for understanding drug action at the genetic level, which is largely hindered by inability to robustly map gene regulatory networks. Here, we use biological prior knowledge of family-to-family gene interactions available in the KEGG database to reveal individual gene-to-gene interaction networks that underlie the gene expression profiles of 2 cell line data sets, sensitive and resistive to neoadjuvant docetaxel breast anticancer drug...
2018: Cancer Informatics
https://www.readbyqxmd.com/read/29448072/a-phase-iii-study-comparing-sb3-a-proposed-trastuzumab-biosimilar-and-trastuzumab-reference-product-in-her2-positive-early-breast-cancer-treated-with-neoadjuvant-adjuvant-treatment-final-safety-immunogenicity-and-survival-results
#3
X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, J-H Ahn, S-A Im, T Sarosiek, S Chatterjee, M Z Wojtukiewicz, Y Shparyk, V Moiseyenko, M Bello, V Semiglazov, Y Lee, J Lim
BACKGROUND: The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanced human epidermal growth factor receptor 2-positive breast cancer was demonstrated in the previous report. Here, we report the final safety, immunogenicity and survival results after neoadjuvant-adjuvant treatment. PATIENTS AND METHODS: Patients were randomised 1:1 to receive neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide)...
February 12, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29445928/efficacy-and-safety-of-trastuzumab-lapatinib-and-paclitaxel-neoadjuvant-treatment-with-or-without-prolonged-exposure-to-anti-her2-therapy-and-with-or-without-hormone-therapy-for-her2-positive-primary-breast-cancer-a-randomised-five-arm-multicentre-open-label
#4
N Masuda, M Toi, N Yamamoto, H Iwata, K Kuroi, H Bando, S Ohtani, T Takano, K Inoue, Y Yanagita, H Kasai, S Morita, T Sakurai, S Ohno
BACKGROUND: Dual blockade of HER2 promises increased pathological complete response (pCR) rate compared with single blockade in the presence of chemotherapy for HER2-positive (+) primary breast cancer. Many questions remain regarding optimal duration of treatment and combination impact of endocrine therapy for luminal HER2 disease. METHODS: We designed a randomised phase II, five-arm study to evaluate the efficacy and safety of lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with/without prolongation of anti-HER2 therapy prior to chemotherapy (18 vs...
February 14, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29440915/effects-of-core-needle-biopsy-and-subsequent-neoadjuvant-chemotherapy-on-molecular-alterations-and-outcome-in-breast-cancer
#5
Lingmin Xie, Xiaolei Li, Qinchuan Wang, Jichun Zhou, Jun Shen, Lixi Luo, Yi Lu, Linbo Wang
Objectives: The aim of our study is to evaluate the effect of core needle biopsy (CNB) and subsequent neoadjuvant chemotherapy (NAC) on the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth hormone receptor 2 (HER2) and Ki67 in breast cancer, and the associated influencing factors. Materials and methods: In this retrospective cohort study, 143 patients with primary operable breast cancer who received NAC were included. ER, PR, HER2 and Ki67 statuses were compared between pretreatment and posttreatment residual samples...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29439778/the-importance-of-histological-assessment-after%C3%A2-neoadjuvant-therapy-and-the-need-for-standardisation
#6
REVIEW
K Naidoo, S E Pinder
Neoadjuvant therapy is increasingly being recognised as a management option for patients with primary invasive breast carcinoma; this may take the form of primary endocrine treatment or primary chemotherapy. Surgical specimens from women treated with neoadjuvant treatments, particularly primary chemotherapy, may cause a challenge for the histopathologist in handling and interpretation and have, in the past, been sampled, evaluated, and reported in a non-standardised way. This limits comparison between clinical trials and potentially provides clinicians and patients with suboptimal prognostic information...
February 10, 2018: Clinical Radiology
https://www.readbyqxmd.com/read/29435853/do-patients-whose-tumor-achieved-a-pathological-response-relapse-at-specific-sites-a-substudy-of-the-eortc-10994-big-1-00-trial
#7
Kim C Aalders, Nathan Touati, Konstantinos Tryfonidis, Mylène Annonay, Saskia Litiere, Jonas Bergh, Alexandre Bodmer, David A Cameron, Hervé R Bonnefoi
PURPOSE: To determine the sites of first distant relapse in patients with or without pCR following neoadjuvant chemotherapy in breast cancer patients enrolled in the EORTC 10994/BIG-1-00 trial. METHODS: We included patients enrolled in the EORTC 10994/BIG-1-00 trial who received at least one chemotherapy cycle before surgery and who had been diagnosed with a distant relapse. pCR was defined as no evidence of residual invasive cancer in the primary tumor and axillary lymph nodes with or without residual ductal carcinoma in situ...
February 12, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29434896/intra-arterial-interventional-therapy-for-inoperable-local-advanced-breast-cancer-a-retrospective-study
#8
Jing Ma, Jin Song, Hai Chen, Cibo Fan, Jiaqi Xie, Xiaodong Qi
The aim of the present study was to evaluate the safety and efficacy of intra-arterial interventional therapy (IAIT) in the treatment of inoperable local advanced breast cancer (LABC). A total of 7 patients with pathologically proven inoperable LABC were included in the present study. Patients received 1-4 cycles of IAIT prior to mastectomy and postoperative adjuvant therapy. The safety and clinical outcomes of IAIT were retrospectively analyzed. Between February 2009 to September 2016, 7 patients received IAIT...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29431574/dynamic-diffuse-optical-tomography-for-monitoring-neoadjuvant-chemotherapy-in-patients-with-breast-cancer
#9
Jacqueline E Gunther, Emerson A Lim, Hyun K Kim, Molly Flexman, Mirella Altoé, Jessica A Campbell, Hanina Hibshoosh, Katherine D Crew, Kevin Kalinsky, Dawn L Hershman, Andreas H Hielscher
Purpose To identify dynamic optical imaging features that associate with the degree of pathologic response in patients with breast cancer during neoadjuvant chemotherapy (NAC). Materials and Methods Of 40 patients with breast cancer who participated in a longitudinal study between June 2011 and March 2016, 34 completed the study. There were 13 patients who obtained a pathologic complete response (pCR) and 21 patients who did not obtain a pCR. Imaging data from six subjects were excluded from the study because either the patients dropped out of the study before it was finished or there was an instrumentation malfunction...
February 12, 2018: Radiology
https://www.readbyqxmd.com/read/29429940/review-of-novel-sentinel-lymph-node-biopsy-techniques-in-breast-cancer-patients-treated-with-neoadjuvant-chemotherapy
#10
REVIEW
Yeliz Emine Ersoy, Huseyin Kadioglu
Breast cancer patients who present with nodal metastasis receive neoadjuvant chemotherapy (NAC) with increasing frequency and can have complete pathologic response after treatment. In this clinical scenario, sentinel node mapping and biopsy are gaining acceptance instead of axillary dissection to avoid morbidity. Biopsy proven positive lymph nodes must be reliably excised and examined after NAC to further decrease the false negativity rate of sentinel lymph node (SLN) surgery. The standard method for axillary staging in breast cancer patients even after NAC is SLN biopsy (SLNB) with a radioisotope, blue dye, or both (dual technique)...
January 31, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29428039/rationale-for-mastectomy-after-neoadjuvant-chemotherapy
#11
Lejla Hadzikadic Gusic, Kendall Walsh, Teresa Flippo-Morton, Terry Sarantou, Danielle Boselli, Richard L White
Neoadjuvant chemotherapy (NAC) reduces tumor size, facilitating the use of breast conservation surgery (BCS). However, mastectomy remains the surgical outcome for certain women. The goal of this study was to determine the rationale for mastectomy after NAC, particularly in women eligible for BCS. Retrospective data were reviewed on patients who received NAC between February 2006 and August 2010 at our institution. Demographics and tumor characteristics were compared between patients who received BCS and mastectomy after NAC...
January 1, 2018: American Surgeon
https://www.readbyqxmd.com/read/29423090/efficacy-of-assessing-circulating-cell-free-dna-using-a-simple-fluorescence-assay-in-patients-with-triple-negative-breast-cancer-receiving-neoadjuvant-chemotherapy-a-prospective-observational-study
#12
Kwonoh Park, Miyoung Woo, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Jin Roh, Gyungyub Gong, Sung-Bae Kim
This study aims to assess cell-free DNA (CFD) by a fluorescence assay as a biomarker for early prediction of a pathologic complete response (pCR) and relapse in patients with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy. Patients with clinical stage II or III TNBC scheduled for neoadjuvant chemotherapy were prospectively enrolled. All patients underwent four cycles of Adriamycin plus cyclophosphamide (AC), followed by four cycles of cisplatin or docetaxel chemotherapy and surgery...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29420367/early-response-assessed-by-contrast-enhanced-ultrasound-in-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy
#13
Ting Dong
The study was aimed to investigate the role of contrast-enhanced ultrasound (CEUS) in evaluating the response of patients with breast cancer after receiving neoadjuvant chemotherapy (NAC). A systematic search was conducted in PubMed, Spring, Wanfang, and CNKI databases from 1923 to December 2016. Based on fixed effect model or randomized effects model, standardized mean difference (SMD) with its 95% confidence interval (95% CI) was calculated in accordance with heterogeneity analysis. Cochran Q and I tests were used to measure heterogeneity...
February 7, 2018: Ultrasound Quarterly
https://www.readbyqxmd.com/read/29413658/processing-and-reporting-of-breast-specimens-in-the-neoadjuvant-setting
#14
REVIEW
Veerle Bossuyt
Standardization of quantification of residual disease in the breast and lymph nodes with routine pathologic macroscopic and microscopic evaluation leads to accurate and reproducible measures of response to neoadjuvant treatment. Multidisciplinary collaboration and correlation of clinical, imaging, gross and microscopic findings is essential. The processing approach to post-neoadjuvant breast cancer surgical specimens and the elements needed in the pathology report are the same regardless of breast cancer subtype or type of neoadjuvant treatment...
March 2018: Surgical Pathology Clinics
https://www.readbyqxmd.com/read/29409738/oca2-rs4778137-polymorphism-predicts-survival-of-breast-cancer-patients-receiving-neoadjuvant-chemotherapy
#15
Xiao-Ping Li, Jian-Yun Lan, Dong-Qin Liu, Hang Zhou, Miao-Miao Qian, Wei-Wei Wang, Man Yang
BACKGROUND: Genome-wide association study (GWAS) studies have showed that single nucleotide polymorphisms (SNPs) in OCA2 gene were associated with the survival of breast cancer patients treated with adjuvant chemotherapy. To further explain the association between OCA2 SNPs and breast cancer survival, we investigated the predictive value of rs4778137 located in OCA2 in local advanced breast cancer patients receiving neoadjuvant chemotherapy. PATIENTS AND METHODS: A case-cohort with 150 breast cancer patients was performed to evaluate the effects of the OCA2 rs4778137 on breast cancer survival...
February 1, 2018: Gene
https://www.readbyqxmd.com/read/29397610/-application-of-decision-curve-on-evaluation-of-mri-predictive-model-for-early-assessing-pathological-complete-response-to-neoadjuvant-therapy-in-breast-cancer
#16
Y J He, X T Li, Z Q Fan, Y L Li, K Cao, Y S Sun, T Ouyang
Objective: To construct a dynamic enhanced MR based predictive model for early assessing pathological complete response (pCR) to neoadjuvant therapy in breast cancer, and to evaluate the clinical benefit of the model by using decision curve. Methods: From December 2005 to December 2007, 170 patients with breast cancer treated with neoadjuvant therapy were identified and their MR images before neoadjuvant therapy and at the end of the first cycle of neoadjuvant therapy were collected. Logistic regression model was used to detect independent factors for predicting pCR and construct the predictive model accordingly, then receiver operating characteristic (ROC) curve and decision curve were used to evaluate the predictive model...
January 23, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29396664/single-arm-neoadjuvant-phase-ii-trial-of-pertuzumab-and-trastuzumab-administered-concomitantly-with-weekly-paclitaxel-followed-by-5-fluoruracil-epirubicin-and-cyclophosphamide-fec-for-stage-i-iii-her2-positive-breast-cancer
#17
Julia Foldi, Sarah Mougalian, Andrea Silber, Donald Lannin, Brigid Killelea, Anees Chagpar, Nina Horowitz, Courtney Frederick, Lawrence Rispoli, Trisha Burrello, Maysa Abu-Khalaf, Kert Sabbath, Tara Sanft, Debra S Brandt, Erin W Hofstatter, Christos Hatzis, Michael P DiGiovanna, Lajos Pusztai
PURPOSE: The purpose of this two-cohort Phase II trial was to estimate the pathologic complete response (pCR: ypT0/is ypN0) rate when trastuzumab plus pertuzumab are administered concurrently during both the taxane and anthracycline phases of paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) neoadjuvant chemotherapy. METHODS: The pCR rates were assessed separately in hormone receptor (HR) positive and negative cases following Simon's two-stage design, aiming to detect a 20% absolute improvement in pCR rates from 50 to 70 and 70 to 90% in the HR-positive and HR-`negative cohorts, respectively...
February 2, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29396328/dedicated-breast-pet-for-detecting-residual-disease-after-neoadjuvant-chemotherapy-in-operable-breast-cancer-a-prospective-cohort-study
#18
Shinsuke Sasada, Norio Masumoto, Noriko Goda, Keiko Kajitani, Akiko Emi, Takayuki Kadoya, Morihito Okada
PURPOSE: Diagnostic methods to evaluate the response to neoadjuvant chemotherapy (NAC) for breast cancer have not been established. Dedicated breast PET (DbPET) is a high-resolution molecular breast imaging method, and we investigated the capability of DbPET to predict residual primary tumors after NAC compared with whole-body PET (WBPET). METHODS: Forty-five patients (47 tumors) underwent WBPET and ring-type DbPET after NAC, and the tumors were completely resected between January 2016 and March 2017...
January 17, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29394628/-a-case-of-skull-base-metastasis-of-breast-cancer-with-dysphasia-odynophagia-and-dysarthria
#19
Hirotoshi Takahashi, Maya Uno, Kazuya Miyoshi
While skull base metastases from breast cancer are not uncommon, there are relatively few reported cases in the literature. We report a case of skull base metastasis of breast cancer that resulted in dysphasia, odynophagia, and dysarthria. The case involved a woman in her 50 s who was diagnosed with cancer of the right breast(cT4N1M0, cStage III B)at another medical institution 9 years previously and who underwent a partial mastectomy and an axillary lymph node dissection following neoadjuvant chemotherapy...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394563/-four-cases-of-occult-breast-cancer-treated-with-breast-conserving-therapy-after-neoadjuvant-chemotherapy
#20
Tetsutaro Miyoshi, Masayuki Shiobara, Kazuo Wakatsuki, Syuka Arai, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihisa Takahashi, Shigeru Yoshioka
We report 4 patients with occult breast cancer(OBC)who underwent breast conserving therapy(BCT)after neoadjuvant chemotherapy(NAC). All patients complained of axillary tumor and were diagnosed by core needle biopsy. Pathological examination of the axillary lymph nodes proved that 3 cases were adenocarcinomas and 1 case was squamous cell carcinoma, but imaging studies could not depict any primary lesions in the breast and other organs. Since distant metastasis was not observed, BCT with axillary lymph node dissection(ALND)was performed after NAC...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
72735
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"